Difference between revisions of "Momelotinib (Ojjaara)"
Jump to navigation
Jump to search
m |
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
||
| Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
===[[Myelofibrosis]]=== | ===[[Myelofibrosis]]=== | ||
| − | # Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, Hogan WJ, Litzow MR, Leontovich A, Kowalski M, Tefferi A. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013 Jun;27(6):1322-7. Epub 2013 Mar 5. [ | + | # Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, Hogan WJ, Litzow MR, Leontovich A, Kowalski M, Tefferi A. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013 Jun;27(6):1322-7. Epub 2013 Mar 5. [https://www.ncbi.nlm.nih.gov/pubmed/23459451 PubMed] |
[[Category:Drug index]] | [[Category:Drug index]] | ||
Revision as of 02:44, 2 December 2016
Mechanism of action
JAK1/2 inhibitor
Preliminary data
Myelofibrosis
- Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, Hogan WJ, Litzow MR, Leontovich A, Kowalski M, Tefferi A. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013 Jun;27(6):1322-7. Epub 2013 Mar 5. PubMed